Skip to main content
Retour
Watch Compare

Cue Biopharma, Inc.

Qualité des données : 100%
CUE
Nasdaq Manufacturing Chemicals
0,29 €
▲ 0,01 € (4,27%)
Cap. Boursière: 27,88 M
Prix
0,29 €
Cap. Boursière
27,88 M
Fourchette du Jour
0,21 € — 0,29 €
Fourchette 52 Semaines
0,17 € — 1,03 €
Volume
10 210 441
Ouverture 0,25 €
Moyenne 50J / 200J
0,29 €
2,53% below
Moyenne 50J / 200J
0,57 €
50,14% below

Quick Summary

Points Clés

Revenue grew 16,44% annually over 5 years — strong growth
Negative free cash flow of -21,86 M
Revenue growth is accelerating — 1Y growth exceeds 5Y average by 179,31%
Capital efficient — spends only 0,64% of revenue on capex

Croissance

Revenue Growth (5Y)
16,44%
Au-dessus de la moyenne du secteur (1,82%)
Revenue (1Y)195,75%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-169,41%
En dessous de la moyenne du secteur (-53,47%)
ROIC-111,66%
Net Margin-96,85%
Op. Margin-96,67%

Sécurité

Debt / Equity
N/A
Current Ratio1,66
Interest Coverage-265,52

Valorisation

PE (TTM)
-1,05
Au-dessus de la moyenne du secteur (-1,47)
P/B Ratio2,10
EV/EBITDAN/A
Dividend YieldN/A

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Manufacturing (1364 pairs)
Métrique Action Médiane du Secteur
P/E -1,1 -1,5
P/B 2,1 1,6
ROE % -169,4 -53,5
Net Margin % -96,9 -41,5
Rev Growth 5Y % 16,4 1,8
D/E — 0,3

All Fundamental Metrics
Growth
Revenue Growth (1Y) 195,75% Revenue Growth (3Y) 123,67%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 16,44% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 27,47 M Net Income (TTM) -26,60 M
ROE -169,41% ROA -73,54%
Gross Margin N/A Operating Margin -96,67%
Net Margin -96,85% Free Cash Flow (TTM) -21,86 M
ROIC -111,66% FCF Growth (3Y) N/A
Safety
Debt / Equity N/A Current Ratio 1,66
Interest Coverage -265,52 Asset Turnover 0,76
Working Capital 10,30 M Tangible Book Value 13,25 M
Dividends
Dividend Yield N/A Payout Ratio N/A
Dividend Growth (3Y) N/A Dividend Growth (5Y) N/A
Consecutive Div Years N/A
Valuation
P/E Ratio -1,05 Forward P/E N/A
P/B Ratio 2,10 P/S Ratio 1,02
PEG Ratio N/A Forward PEG N/A
EV/EBITDA N/A Fwd EV/EBITDA N/A
Forward P/S N/A Fwd Earnings Yield N/A
FCF Yield -78,42%
Market Cap 27,88 M Enterprise Value 16,18 M
Per Share
EPS (Diluted TTM) -0,28 Revenue / Share 0,28
FCF / Share -0,22 OCF / Share -0,22
EPS CAGR (1Y) N/A EPS CAGR (5Y) N/A
EPS CAGR (10Y) N/A
Efficiency
CapEx / Revenue 0,64% FCF Conversion 82,19%
SBC-Adj. FCF -27,58 M Growth Momentum 179,31

Income Statement

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 27,47 M 9,29 M 5,49 M 1,25 M 14,94 M
Net Income -26,60 M -40,67 M -50,73 M -53,01 M -44,16 M
EPS (Diluted) -0,28 -0,72 -1,11 -1,49 —
Gross Profit — — — — —
Operating Income -26,55 M -41,50 M -52,15 M -53,22 M -43,71 M
EBITDA — — — — —
R&D Expenses 37,74 M 36,30 M 40,80 M 38,58 M 41,35 M
SG&A Expenses — — — — —
D&A 958 000,0 397 000,0 556 000,0 922 216,0 1,26 M
Interest Expense 100 000,0 100 000,0 130 000,0 -713 815,0 —
Income Tax 500 000,0 400 000,0 — 0,0 495 000,0

Balance Sheet

Annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 42,21 M 32,19 M 61,53 M 91,28 M 83,40 M
Total Liabilities 15,78 M 14,69 M 24,45 M 25,60 M 17,91 M
Shareholders' Equity 26,43 M 17,50 M 37,09 M 65,68 M 65,49 M
Total Debt — 37 000,0 4,04 M 8,07 M —
Cash & Equivalents 27,14 M 22,46 M 48,51 M 51,61 M 64,37 M
Current Assets 36,98 M 25,14 M 51,45 M 77,19 M 68,47 M
Current Liabilities 13,49 M 13,69 M 17,08 M 11,55 M 12,79 M